Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) Shares Outstanding (Weighted Average) (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $4.7 million as the latest value for Q3 2018.

  • Quarterly Shares Outstanding (Weighted Average) fell 12.64% to $4.7 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Sep 2018, down 12.64% year-over-year, with the annual reading at $6.4 million for FY2017, 549.23% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $4.7 million in Q3 2018 for Armata Pharmaceuticals, down from $16.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $182.5 million in Q1 2014 to a low of $588350.0 in Q1 2016.
  • Historically, Shares Outstanding (Weighted Average) has averaged $14.3 million across 5 years, with a median of $4.7 million in 2018.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 97.67% in 2015 and later surged 692.74% in 2018.
  • Year by year, Shares Outstanding (Weighted Average) stood at $3.7 million in 2014, then surged by 44.43% to $5.4 million in 2015, then tumbled by 81.82% to $983846.0 in 2016, then soared by 549.23% to $6.4 million in 2017, then dropped by 27.16% to $4.7 million in 2018.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ARMP at $4.7 million in Q3 2018, $16.5 million in Q2 2018, and $13.3 million in Q1 2018.